you're reading...
Metrics, Public Policy, Random Rants, Resources

New Healthcare study…

It’s really good that people are beginning to look seriously at the cost drivers in healthcare. Part of the “Evil Obamacare” is that its opened up some good new sources. So here is an introduction to the
Health Cost Institute and their latest study. Read it here. Note that this study is not your usual four year out of date masterpiece and also note that it includes vast quantities of private insurer data that was previously unavailable. Also note there is a significant mention of Behavioral Health issues.



About barkie19

I'm a Healthcare Information Technology consultant who happens to specialize in the Public Behavioral Health world. Things have been at the status quo for a while and I believe its time to change the conversation. Talk to me, please.


One thought on “New Healthcare study…

  1. Up to 60% of individuals with schizophrenia do not take their antipsychotic medications as prescribed, which can lead to symptom relapse, decreased functioning, hospitalization, and increased healthcare costs. Whereas a variety of internet- and mobile phone-based applications have been developed to improve health outcomes such as medication adherence for a number of medical and psychiatric disorders, no such applications have been developed for individuals with schizophrenia. We will utilize the R34 mechanism to develop and evaluate the feasibility and acceptability of an ecological momentary intervention (EMI), which is integrated into an individuals’ daily life where it is most relevant, for improving antipsychotic adherence. Primary features of the EMI that will be installed on mobile SmartPhones include: development of an interactive tool that provides individuals with reminders to take their medications as prescribed, queries them on their intentions to take their medication or not, collects real-time psychiatric symptom and side effect data that can be displayed for individuals and their clinicians, and provides individuals with the capability of communicating with their clinicians about problems they may be experiencing with their medications. In addition to gathering preliminary data on whether the intervention improves antipsychotic adherence, we will also evaluate whether individuals’ levels of positive and negative psychotic symptoms and various domains of neuropsychological functioning correlate with the feasibility of using the program and its overall acceptability by individuals. Completion of this developmental study will enable us to develop and refine the research strategies to be utilized in a subsequent larger-scale study of the intervention.

    Posted by gold price | June 17, 2012, 4:06 AM
%d bloggers like this: